Protocol Ledger

NCT05583110 · Phase II · TERMINATED

Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer

Interventional Phase II clinical trial protocol NCT05583110 sponsored by Spanish Breast Cancer Research Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-08 Enrollment: 13 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05583110
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)13 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05583110
Protocol FieldVerified Registry Value
NCT IdentifierNCT05583110
Consolidated Lead SponsorSpanish Breast Cancer Research Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment13 participants (ACTUAL)
Registered Start Date2023-03-08
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI